Table 1.
Selectively profile of NBC (A) and dNBC (B)
| Kinase | Residual activity (% of control) |
|---|---|
| A | |
| CK2 | 6 |
| PIM3 | 6 |
| PIM1 | 11 |
| PKBb | 14 |
| HIPK2 | 21 |
| DYRK1A | 24 |
| VEG-FR | 24 |
| DAPK1 | 26 |
| CAMK1 | 28 |
| ERK8 | 29 |
| PIM2 | 36 |
| SRPK1 | 38 |
| MNK1 | 43 |
| BTK | 45 |
| GCK | 48 |
| FGF-R1 | 49 |
| MINK1 | 50 |
| IR | 52 |
| MLK3 | 52 |
| DYRK3 | 54 |
| RSK2 | 55 |
| MAPKAP-K3 | 56 |
| SGK1 | 58 |
| HIPK3 | 61 |
| Aurora A | 61 |
| MST2 | 64 |
| PRK2 | 65 |
| IRR | 66 |
| ERK1 | 68 |
| CK1 | 68 |
| PAK4 | 70 |
| DYRK2 | 70 |
| IRAK4 | 70 |
| NEK6 | 71 |
| TTK | 71 |
| IKKb | 72 |
| MNK2 | 73 |
| AMPK | 75 |
| MARK4 | 76 |
| GSK3b | 76 |
| MARK2 | 76 |
| JNK1 | 77 |
| p38 g MAPK | 77 |
| NUAK1 | 78 |
| CLK2 | 78 |
| p38a MAPK | 78 |
| S6K1 | 79 |
| PHK | 79 |
| CDK2-Cyc A | 80 |
| MKK1 | 80 |
| SmMLCK | 80 |
| EF2 K | 80 |
| HER4 | 80 |
| IKKe | 81 |
| IGF-1R | 81 |
| EPH-A2 | 81 |
| YES1 | 83 |
| MARK1 | 83 |
| MKK2 | 84 |
| PKCa | 84 |
| CHK2 | 85 |
| MPSK1 | 85 |
| EPH-B3 | 87 |
| Lck | 87 |
| PKD1 | 87 |
| JNK2 | 88 |
| MAPKAP-K2 | 88 |
| BRSK2 | 88 |
| SYK | 89 |
| PKCy | 89 |
| MARK3 | 90 |
| MEKK1 | 91 |
| STK33 | 91 |
| JNK3 | 91 |
| MSK1 | 92 |
| RIPK2 | 93 |
| CAMKKb | 93 |
| Aurora B | 93 |
| TAOl | 93 |
| ASK1 | 94 |
| LKB1 | 94 |
| TrkA | 95 |
| PAK5 | 96 |
| CHK1 | 98 |
| PKBa | 98 |
| p38b MAPK | 98 |
| RSK1 | 99 |
| MLK1 | 99 |
| PRAK | 100 |
| MELK | 100 |
| BRK | 101 |
| MKK6 | 101 |
| PLK1 | 101 |
| CSK | 101 |
| BRSK1 | 101 |
| PDK1 | 101 |
| EPH-A4 | 101 |
| ROCK 2 | 102 |
| p38d MAPK | 104 |
| PKCz | 104 |
| TIE2 | 104 |
| HIPK1 | 105 |
| TAK1 | 105 |
| ZAP70 | 105 |
| PAK2 | 106 |
| ERK2 | 106 |
| TBK1 | 107 |
| Src | 107 |
| NEK2a | 108 |
| ABL | 109 |
| JAK2 | 110 |
| EPH-B2 | 112 |
| PKA | 113 |
| EPH-B4 | 114 |
| EPH-B1 | 118 |
| PAK6 | 120 |
| M5T4 | 125 |
| B | |
| DYRK1A | 3 |
| ERK8 | 4 |
| GSK3b | 6 |
| PIM1 | 10 |
| TAO1 | 12 |
| PIM3 | 12 |
| PRK2 | 13 |
| CLK2 | 18 |
| DYRK3 | 19 |
| AMPK | 20 |
| MKK1 | 21 |
| HIPK2 | 22 |
| SmMLCK | 23 |
| BRSK2 | 24 |
| CDK2-Cyc A | 27 |
| IRR | 29 |
| RSK1 | 29 |
| MKK2 | 31 |
| DYRK2 | 32 |
| MNK2 | 38 |
| MNK1 | 39 |
| DAPK1 | 41 |
| ASK1 | 43 |
| GCK | 45 |
| BTK | 46 |
| VEG-FR | 49 |
| IRAK4 | 49 |
| LKB1 | 49 |
| PRAK | 50 |
| EF2 K | 51 |
| MEKK1 | 51 |
| TTK | 52 |
| RSK2 | 52 |
| PIM2 | 53 |
| S6K1 | 55 |
| CK2 | 55 |
| MLK3 | 56 |
| MST2 | 58 |
| NUAK1 | 59 |
| SGK1 | 60 |
| PAK4 | 61 |
| CK1 | 61 |
| ERK1 | 62 |
| MINK1 | 62 |
| PKD1 | 63 |
| CAMKKb | 64 |
| Aurora B | 64 |
| JNK1 | 65 |
| PKCz | 66 |
| PHK | 67 |
| HIPK3 | 67 |
| CAMK1 | 68 |
| RIPK2 | 68 |
| MELK | 68 |
| SRPK1 | 68 |
| EPH-A2 | 68 |
| PKBb | 69 |
| HIPK1 | 70 |
| CHK1 | 70 |
| IKKe | 71 |
| EPH-B3 | 71 |
| HER4 | 72 |
| MSK1 | 72 |
| TBK1 | 73 |
| FGF-R1 | 74 |
| ROCK 2 | 74 |
| CHK2 | 74 |
| IR | 74 |
| MARK4 | 75 |
| MPSK1 | 75 |
| IKKb | 76 |
| p38a MAPK | 77 |
| STK33 | 78 |
| p38 g MAPK | 78 |
| TAK1 | 78 |
| NEK6 | 78 |
| YES1 | 79 |
| MAPKAP-K2 | 80 |
| Lck | 80 |
| PAK2 | 81 |
| IGF-1R | 81 |
| MLK1 | 81 |
| MARK2 | 81 |
| ERK2 | 82 |
| PAK5 | 83 |
| EPH-B4 | 84 |
| TrkA | 85 |
| JNK2 | 86 |
| MAPKAP-K3 | 87 |
| ABL | 87 |
| BRSK1 | 87 |
| Aurora A | 87 |
| MARK3 | 88 |
| MARK1 | 89 |
| p38d MAPK | 90 |
| EPH-A4 | 90 |
| Src | 91 |
| JNK3 | 92 |
| MKK6 | 92 |
| JAK2 | 92 |
| SYK | 93 |
| PKCa | 93 |
| PLK1 | 95 |
| ZAP70 | 97 |
| PKA | 97 |
| NEK2a | 98 |
| p38b MAPK | 101 |
| PKCγ | 101 |
| MST4 | 103 |
| BRK | 103 |
| CSK | 103 |
| TIE2 | 104 |
| PAK6 | 105 |
| PDK1 | 106 |
| EPH-B2 | 109 |
| PKBa | 111 |
| EPH-B1 | 114 |
Inhibition assays were performed at a concentration of 10 μM of the indicated inhibitor under conditions referenced in the text. The residual activity are sorted in increasing order